Virbac : Webcast feedback: H1 ahead of guidance and management confident on the group’s model and capacity to deliver
>Confidence and visibility signalled by management - During its webcast, management underscored market share gains and its regular outperformance of the veterinary market. Our key takeaways are:1/ 2024 guidance is maintained (operating margin 2024E:16%) despite H1 results that topped consensus expectations: it seems cautious in our view, as we indicated yesterday morning (see our First Take), but the CFO highlighted weaker growth in H2 and historic seasonality (w...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.